Protective effect of dl-α-lipoic acid on cyclophosphamide induced hyperlipidemic cardiomyopathy

Yenjerla Mythili, Sudharsan Periyasamy Thandavan, Sudhahar Varadarajan, Palaninathan Varalakshmi

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Cyclophosphamide is a potent alkylating agent used in cancer chemotherapy and immunosuppression. The present study is aimed at evaluating the role of a potent antioxidant lipoic acid in cyclophosphamide induced hyperlipidemic cardiomyopathy. Adult male Wistar rats were divided into four treatment groups. Two groups received single intraperitoneal injection of cyclophosphamide (200 mg/kg body weight) to induce cardiotoxicity, one of these groups received lipoic acid treatment (25 mg/kg body weight, orally for 10 days). A vehicle treated control group and a lipoic acid drug control were also included. Cyclophosphamide administration resulted in abnormal elevation of serum lipids. Similarly in the cardiac tissue, the levels of free cholesterol, esterified cholesterol, triglycerides were increased significantly (P < 0.05) while the levels of phospholipids and free fatty acids were reduced significantly unlike serum (P < 0.05). Serum Low Density Lipoprotein (LDL) and Very Low Density Lipoprotein (VLDL) cholesterol increased significantly (P < 0.05) while High Density Lipoprotein (HDL) cholesterol (P < 0.05) decreased significantly when compared to controls. These changes corroborated with the abnormal distortion in the activities of lipid metabolizing enzymes in cyclophosphamide treated group. Supplementation of lipoic acid reverted these abnormalities in the lipid levels and activities of lipid metabolizing enzymes to near normalcy after cyclophosphamide administration.

Original languageEnglish (US)
Pages (from-to)92-96
Number of pages5
JournalEuropean Journal of Pharmacology
Volume543
Issue number1-3
DOIs
StatePublished - Aug 14 2006

Fingerprint

Thioctic Acid
Cardiomyopathies
Cyclophosphamide
Lipids
Serum
Cholesterol
Body Weight
VLDL Cholesterol
Drug and Narcotic Control
Alkylating Agents
Enzymes
Intraperitoneal Injections
LDL Lipoproteins
Nonesterified Fatty Acids
Immunosuppression
HDL Cholesterol
Wistar Rats
Phospholipids
Triglycerides
Antioxidants

Keywords

  • Cyclophosphamide
  • Heart
  • Hyperlipidemia
  • Lipoic acid
  • Serum

ASJC Scopus subject areas

  • Pharmacology

Cite this

Protective effect of dl-α-lipoic acid on cyclophosphamide induced hyperlipidemic cardiomyopathy. / Mythili, Yenjerla; Periyasamy Thandavan, Sudharsan; Varadarajan, Sudhahar; Varalakshmi, Palaninathan.

In: European Journal of Pharmacology, Vol. 543, No. 1-3, 14.08.2006, p. 92-96.

Research output: Contribution to journalArticle

Mythili, Yenjerla ; Periyasamy Thandavan, Sudharsan ; Varadarajan, Sudhahar ; Varalakshmi, Palaninathan. / Protective effect of dl-α-lipoic acid on cyclophosphamide induced hyperlipidemic cardiomyopathy. In: European Journal of Pharmacology. 2006 ; Vol. 543, No. 1-3. pp. 92-96.
@article{6c08136abfe24ba5952d6ee5f7c60750,
title = "Protective effect of dl-α-lipoic acid on cyclophosphamide induced hyperlipidemic cardiomyopathy",
abstract = "Cyclophosphamide is a potent alkylating agent used in cancer chemotherapy and immunosuppression. The present study is aimed at evaluating the role of a potent antioxidant lipoic acid in cyclophosphamide induced hyperlipidemic cardiomyopathy. Adult male Wistar rats were divided into four treatment groups. Two groups received single intraperitoneal injection of cyclophosphamide (200 mg/kg body weight) to induce cardiotoxicity, one of these groups received lipoic acid treatment (25 mg/kg body weight, orally for 10 days). A vehicle treated control group and a lipoic acid drug control were also included. Cyclophosphamide administration resulted in abnormal elevation of serum lipids. Similarly in the cardiac tissue, the levels of free cholesterol, esterified cholesterol, triglycerides were increased significantly (P < 0.05) while the levels of phospholipids and free fatty acids were reduced significantly unlike serum (P < 0.05). Serum Low Density Lipoprotein (LDL) and Very Low Density Lipoprotein (VLDL) cholesterol increased significantly (P < 0.05) while High Density Lipoprotein (HDL) cholesterol (P < 0.05) decreased significantly when compared to controls. These changes corroborated with the abnormal distortion in the activities of lipid metabolizing enzymes in cyclophosphamide treated group. Supplementation of lipoic acid reverted these abnormalities in the lipid levels and activities of lipid metabolizing enzymes to near normalcy after cyclophosphamide administration.",
keywords = "Cyclophosphamide, Heart, Hyperlipidemia, Lipoic acid, Serum",
author = "Yenjerla Mythili and {Periyasamy Thandavan}, Sudharsan and Sudhahar Varadarajan and Palaninathan Varalakshmi",
year = "2006",
month = "8",
day = "14",
doi = "10.1016/j.ejphar.2006.06.007",
language = "English (US)",
volume = "543",
pages = "92--96",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Protective effect of dl-α-lipoic acid on cyclophosphamide induced hyperlipidemic cardiomyopathy

AU - Mythili, Yenjerla

AU - Periyasamy Thandavan, Sudharsan

AU - Varadarajan, Sudhahar

AU - Varalakshmi, Palaninathan

PY - 2006/8/14

Y1 - 2006/8/14

N2 - Cyclophosphamide is a potent alkylating agent used in cancer chemotherapy and immunosuppression. The present study is aimed at evaluating the role of a potent antioxidant lipoic acid in cyclophosphamide induced hyperlipidemic cardiomyopathy. Adult male Wistar rats were divided into four treatment groups. Two groups received single intraperitoneal injection of cyclophosphamide (200 mg/kg body weight) to induce cardiotoxicity, one of these groups received lipoic acid treatment (25 mg/kg body weight, orally for 10 days). A vehicle treated control group and a lipoic acid drug control were also included. Cyclophosphamide administration resulted in abnormal elevation of serum lipids. Similarly in the cardiac tissue, the levels of free cholesterol, esterified cholesterol, triglycerides were increased significantly (P < 0.05) while the levels of phospholipids and free fatty acids were reduced significantly unlike serum (P < 0.05). Serum Low Density Lipoprotein (LDL) and Very Low Density Lipoprotein (VLDL) cholesterol increased significantly (P < 0.05) while High Density Lipoprotein (HDL) cholesterol (P < 0.05) decreased significantly when compared to controls. These changes corroborated with the abnormal distortion in the activities of lipid metabolizing enzymes in cyclophosphamide treated group. Supplementation of lipoic acid reverted these abnormalities in the lipid levels and activities of lipid metabolizing enzymes to near normalcy after cyclophosphamide administration.

AB - Cyclophosphamide is a potent alkylating agent used in cancer chemotherapy and immunosuppression. The present study is aimed at evaluating the role of a potent antioxidant lipoic acid in cyclophosphamide induced hyperlipidemic cardiomyopathy. Adult male Wistar rats were divided into four treatment groups. Two groups received single intraperitoneal injection of cyclophosphamide (200 mg/kg body weight) to induce cardiotoxicity, one of these groups received lipoic acid treatment (25 mg/kg body weight, orally for 10 days). A vehicle treated control group and a lipoic acid drug control were also included. Cyclophosphamide administration resulted in abnormal elevation of serum lipids. Similarly in the cardiac tissue, the levels of free cholesterol, esterified cholesterol, triglycerides were increased significantly (P < 0.05) while the levels of phospholipids and free fatty acids were reduced significantly unlike serum (P < 0.05). Serum Low Density Lipoprotein (LDL) and Very Low Density Lipoprotein (VLDL) cholesterol increased significantly (P < 0.05) while High Density Lipoprotein (HDL) cholesterol (P < 0.05) decreased significantly when compared to controls. These changes corroborated with the abnormal distortion in the activities of lipid metabolizing enzymes in cyclophosphamide treated group. Supplementation of lipoic acid reverted these abnormalities in the lipid levels and activities of lipid metabolizing enzymes to near normalcy after cyclophosphamide administration.

KW - Cyclophosphamide

KW - Heart

KW - Hyperlipidemia

KW - Lipoic acid

KW - Serum

UR - http://www.scopus.com/inward/record.url?scp=33746210028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746210028&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2006.06.007

DO - 10.1016/j.ejphar.2006.06.007

M3 - Article

C2 - 16814280

AN - SCOPUS:33746210028

VL - 543

SP - 92

EP - 96

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-3

ER -